Dare Bioscience

Executive Summary

Daré Bioscience is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for women's health, addressing unmet needs in contraception, vaginal health, and fertility. The company's pipeline features three lead candidates: a hormone-free intravaginal ring for contraception (DARE-HRT), a topical gel for vulvovaginal atrophy and dyspareunia associated with menopause (DARE-VVA), and a vaginal gel for bacterial vaginosis (DARE-BV). These products aim to provide safer, more effective alternatives to existing treatments, leveraging novel mechanisms and delivery systems. Daré has advanced these programs through clinical development, with key data readouts and regulatory milestones anticipated in the near term. The company operates as a publicly traded entity (NASDAQ: DARE) and has demonstrated a commitment to addressing significant gaps in women's healthcare, a market with substantial growth potential and limited innovation. Its focused pipeline and strategic partnerships position it for potential value inflection in the coming quarters.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line results for DARE-BV (bacterial vaginosis gel)60% success
• Q1 2027Initiation of Phase 2b trial for DARE-VVA (vulvovaginal atrophy gel)50% success
• Q2 2027Potential partnership or licensing deal for DARE-HRT (contraceptive ring)40% success